Bausch Health's ARESTIN Marks 25 Years as Sole FDA-Approved Local Antibiotic for Periodontitis
Event summary
- ARESTIN (minocycline HCl) Microspheres celebrates 25 years as the only FDA-approved locally applied antibiotic for periodontitis treatment.
- Bausch Health's OraPharma highlights ARESTIN's role in addressing a gap in periodontal disease management with targeted antibiotic delivery.
- Periodontal disease affects over 1 billion people globally, with ARESTIN used as an adjunct to scaling and root planing (SRP) procedures.
- OraPharma expands commercial reach into Canada and Puerto Rico to improve access to periodontal treatment options.
The big picture
Bausch Health's celebration of ARESTIN's 25-year milestone underscores the enduring need for targeted treatments in periodontal disease management, a condition affecting over 1 billion people globally. The product's unique FDA approval status positions it as a cornerstone in Bausch Health's dentistry division, OraPharma, while recent market expansions signal a strategic push to address unmet needs in key regions. The company's focus on innovation and collaboration with dental professionals highlights its ambition to maintain leadership in a competitive healthcare landscape.
What we're watching
- Product Differentiation
- Whether ARESTIN can maintain its unique FDA-approved status amid potential competitive pressures in the periodontal treatment market.
- Market Expansion
- The pace at which OraPharma can scale its commercial presence in newly entered markets like Canada and Puerto Rico.
- Innovation Pipeline
- How Bausch Health leverages ARESTIN's legacy to drive future innovation in periodontal care and deepen collaboration with dental professionals.
Related topics